Somatropin

**Product:** somatropin (Nutropin AQ® NuSpin® 5 and 20) (line-extension)

**Class of Drugs:** growth hormone replacement

**Reason for Use:** growth hormone deficiency; growth failure associated with chronic renal insufficiency; Turner syndrome

**Manufacturer:** Hoffmann-La Roche Limited

**Date of Review:** February 5, 2014

**CED Recommendation**

The CED recommended that Nutropin AQ® NuSpin® 5 and Nutropin AQ® NuSpin® 20 be funded according to the same criteria as Nutropin AQ® NuSpin® 10. Nutropin AQ® NuSpin® 5 and 20 are two new dosage strengths of Nutropin AQ® NuSpin® 10. The three products are proportionally formulated and priced.

**Executive Officer Decision***

Based on the CED’s recommendation and an agreement with the manufacturer, the Executive Officer decided to fund Nutropin AQ® NuSpin® 5 and Nutropin AQ® NuSpin® 20 according to the same criteria as Nutropin AQ® NuSpin® 10.

**Funding Status***

Funded through the Ontario Drug Benefit’s (ODB) Exceptional Access Program and through the Special Drugs Program according to specific criteria.

*This information is current as of the posting date of the document. For the most up-to-date information on Executive Officer decision and funding status, see: [www.health.gov.on.ca/en/pro/programs/drugs/status_single_source_subm.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/status_single_source_subm.aspx).*
Highlights of Recommendation:

- Nutropin AQ® NuSpin® 10 (somatropin10mg/2mL) has been funded by the Ontario Public Drug Programs (OPDP) since January 2013. Nutropin AQ® NuSpin® 5 and 20 (somatropin 5mg/2mL and 20mg/2mL) are two new dosage strengths.
- Nutropin AQ® NuSpin® 5, 10 and 20 are proportionally formulated and priced.
- Overall, Nutropin AQ® NuSpin® 5 and 20 provide added dosing options at no additional cost to the program.

Background:

Nutropin AQ® (somatropin) is a growth hormone replacement product. Various somatropin products are funded through the OPDP’s Special Drugs Program and Exceptional Access Program.

Detailed Discussions:

No additional relevant details.

Committee to Evaluate Drugs (CED)

The Committee to Evaluate Drugs (CED) is comprised of practicing physicians, pharmacists, health economists, and patient representatives. In conducting its review, the CED considers data contained in the drug manufacturer’s submission, input provided by patient groups, findings from the national Common Drug Review and the pan-Canadian Oncology Drug Review, and other scientific information as necessary.

For more information, please contact:
Ministry of Health and Long-Term Care
Ontario Public Drug Programs
Hepburn Block, 9th Floor
80 Grosvenor Street, Queen’s Park
Toronto, Ontario  M7A 1R3